Primary Objective To investigate whether combination therapy of high dose oral N-acetylcysteine NAC) and intravenous (IV) sodium bicarbonate can further reduce incidence of contrast induced nephropathy (CIN) in patients with baseline renal impairment undergoing elective percutaneous coronary intervention (PCI).